Presently, the MAT only recommends serologic COVID-19 antibody testing in the following settings: 1) subset of acutely ill patients; 2) focused epidemiologic surveillance during the ongoing outbreak and post-outbreak in vulnerable populations; 3) general epidemiologic surveillance; and, 4) as a tool in studying long-term outcomes in individuals with symptomatic and asymptomatic COVID-19.

Download the Document